Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda Files Japan NDA for Cabozantinib, Exelixis’ RCC Treatment
April 26, 2019
- Daiichi Sankyo Aims to File Yescarta in Japan by Year-End
April 26, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Delgocitinib Shows Good PIII Results in Pediatric Atopic Dermatitis: JT, Torii
April 26, 2019
- Ohara Obtains Exclusive Rights to Biliary Tract Cancer Drug
April 26, 2019
- Daiichi Sells Nihonbashi Building to Raise Funds for Oncology R&D
April 26, 2019
- Fujifilm Toyama Chemical Files Solithromycin for ENT Infection Diseases
April 26, 2019
- Chugai Rings Up Record Q1 Earnings on Brisk New Drug Sales
April 25, 2019
- Boehringer’s Japan Ethical Drug Sales in 2018 Sink 18.4% on Micardis Cliff
April 25, 2019
- Mitsubishi Tanabe Slashes FY2018 Earnings Forecast
April 25, 2019
- Chugai to Erect New Manufacturing Building for Small, Middle Molecule APIs
April 25, 2019
- Over 170 Staffers to Quit Chugai at June-End: Voluntary Redundancy
April 25, 2019
- Kyowa Kirin Seeks Additional Indication for Orkedia
April 25, 2019
- Poxel’s Novel Diabetes Med One Step Closer to World’s 1st Launch, Japan Chief Says Physicians’ Trust Holds Key
April 24, 2019
- Aducanumab Termination Was Wrenching Decision: Eisai CEO
April 24, 2019
- In Authorized Generic Spree, Daiichi Sankyo Espha Focuses More on “Popularization” than “Sales” When It Comes to Cancer AGs
April 24, 2019
- Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019
- Boehringer Seeks Additional Indication for Ofev
April 23, 2019
- Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
April 23, 2019
- Banned Doping Substance Contamination on API Production Line: Sawai Report
April 23, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…